Book a demo
Research & KnowledgeEvent: September 6, 2026

Zyndio published a recent trial combining GLP-1 therapy with resistance training showing participants retained 92% of their lean mass while losing significant body fat.

Published

Signal category

Research & Knowledge

Quote

A recent trial combining GLP-1 therapy with resistance training showed participants retained 92% of their lean mass while losing significant body fat.

Brett Hudson|Zyndio team

Company

Zyndio

Peptides • Performance • Prescriptions • Doctor Visits

Industry
Public Health
Company size
1 employees

Physician Guided Care, Built Around Your Goals. Every program begins with a board certified licensed medical doctor reviewing your case. No treatment is dispensed without physician approval, and prescriptions are fulfilled by U.S.-licensed pharmacies.

Founded 2026

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.

Zyndio published a recent trial combining GLP-1 therapy with resistance training showing participants retained 92% of their lean mass while losing significant body fat. | SeedOps